Recent progress in cell-based delivery systems, such as Treg cell-mediated transport of drug-loaded liposomes to tumor cells, provided an additional promising strategy to enhance cancer immunotherapy, especially through the delivery of IL-2 and immune checkpoint inhibitors [146]. This evidence concerns the gene IL2 and cancer.